Biotech’s barriers to scale aren’t accidental – they’re structural.
To unlock the bioeconomy, we must design out the bottlenecks in infrastructure, translation, and capital from the start.

Biotech’s frontier is no longer technical – it’s economic.
To scale, we must design industrial systems where viability is built in from the start, not added as an afterthought.

Breakthroughs in precision fermentation, strain design, and process optimization have reshaped the edges of what’s possible. Yet much of industrial biotech remains stalled – technically sound but economically unviable.

In this essay, Massimo Portincaso explores how biomanufacturing, and particularly precision fermentation, signals more than a technological breakthrough. It marks the rise of a new industrial logic – one no longer centered on extraction, but on nature co-design.

When we chose the name Arsenale, we were not looking for a metaphor. We were aligning our mission.